Group 1 - The core viewpoint of the article highlights recent developments in convertible bonds and shareholder actions of specific companies [1] Group 2 - The company Tianhe Solar's convertible bond holders have reached a 20% holding ratio [1] - The shareholder of Shouyu Pingmin plans to reduce their stake by no more than 3% [1] - The convertible bonds of Shengxun and Tianchuang will not undergo adjustments [1]

Mergers and Acquisitions - Antong Holdings has decided to terminate the issuance of shares for asset acquisition and related transactions, which included plans to acquire 100% of China Foreign Container Transport Co., Ltd. and 70% of Guangzhou Merchants Roll-on Roll-off Transport Co., Ltd. from China Merchants Energy Transportation Co., Ltd. [1] - Yapu Co., Ltd. plans to purchase approximately 54.50% of shares in Shanghai Yingshuang Electric Technology Co., Ltd. for about 578 million yuan using its own funds [2] Shareholding Changes - Shareholder Zhou Xin of Zhixin Precision plans to reduce his holdings by up to 3% of the total shares, which amounts to a maximum of 1.6 million shares, within three months starting from 15 trading days after the announcement [3] - Wuhu Gaoxin Yida intends to reduce its holdings in Focase Technology by up to 2.9494% of the total shares, equating to a maximum of 250,220 shares, within three months starting from 15 trading days after the announcement [4] - Qin Guangxia, a major shareholder and senior management of Shuyupingmin, plans to reduce her holdings by up to 3% of the total shares, which is a maximum of 12.07 million shares, between June 19, 2025, and September 18, 2025 [5] Risk Matters - Jinghua Laser has experienced a significant stock price increase of 46.44% over four consecutive trading days, but the company acknowledges that its cultural and creative business has considerable unpredictability and volatility [6] - Youfu Co., Ltd. has reported that there have been no significant changes in its recent operating conditions or external business environment, despite its stock price deviating by over 20% in three consecutive trading days [7] - KJ Intelligent has confirmed that its recent daily operations are normal, with no significant changes in market conditions or industry policies, despite its stock price deviating by over 30% in three consecutive trading days [8]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-045 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于持股 5%以上股东、董事、高级管理人员减持股份预披露的公告 公司持股 5%以上股东、董事、高级管理人员秦光霞女士保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示 1、漱玉平民大药房连锁股份有限公司（以下简称"公司"或"发行人"）持股 5%以上 股东、董事、高级管理人员秦光霞女士持有公司股份 73,440,000 股（占公司总股本比例为 18.25%），计划在本公告发布之日起 15 个交易日后的 3 个月内（即 2025 年 6 月 19 日至 2025 年 9 月 18 日），以集中竞价和/或大宗交易方式共计减持本公司股份不超过 12,070,918 股， 占公司总股本的 3%。 注：截至 2025 年 5 月 26 日，公司总股本为 405,352,766 股，扣除回购专户中 ...

Core Viewpoint - The competition among major platforms like Ele.me, JD.com, and Meituan in the food delivery sector has expanded into the pharmaceutical category, leading to a significant rise in the instant retail of medicines, with platforms investing in traffic resources, supply chains, and innovative marketing strategies [1][4]. Group 1: Market Dynamics - The instant retail of pharmaceuticals is experiencing rapid growth, becoming a crucial part of the outpatient pharmaceutical retail market [1][4]. - JD Health's "Buy Medicine in Seconds" feature has seen a threefold increase in order volume due to enhanced traffic resources [4][6]. - The instant retail sector is evolving from high-frequency to low-frequency demand, now covering a full range of categories, including pharmaceuticals [5][6]. Group 2: Platform Strategies - JD.com has prominently featured "24h Delivery of Medicines" on its app, enhancing visibility and traffic for its instant retail services [3][4]. - Meituan has launched its instant retail brand "Meituan Flash Purchase," further intensifying competition in the pharmaceutical retail space [4][6]. - Taobao's instant retail service has been upgraded to "Taobao Flash Purchase," which includes a significant category for purchasing medicines [3][4]. Group 3: Industry Trends - The transformation of physical pharmacies is driving the adoption of instant retail, as many pharmacies are closing, leading to a competitive environment where digital solutions are essential [7][8]. - The integration of online medical services with instant retail is creating a comprehensive service model for users, enhancing the purchasing experience [7][8]. - The collaboration among platforms, pharmaceutical companies, and pharmacies is deepening, allowing for more effective marketing and sales strategies [8][10]. Group 4: Financial Performance - One Heart Hall's new retail segment saw a 47.6% year-on-year increase in revenue, with the O2O instant retail channel contributing 78.2% [15][16]. - Yifeng Pharmacy reported online sales of 2.127 billion yuan in 2024, with 1.721 billion yuan coming from O2O, accounting for 80.9% of total online sales [16][17]. - The overall trend indicates that if online medical insurance is fully opened, the share of instant retail in physical pharmacies could rise to 32.1% by 2030 [16][17]. Group 5: Future Outlook - The competition for instant retail in pharmaceuticals among major platforms is expected to continue, with Douyin's unique position in social media marketing presenting both opportunities and challenges [18]. - The penetration of instant retail in lower-tier markets is anticipated to grow, making it a significant growth driver in the outpatient pharmaceutical retail market [18].

Core Viewpoint - The retail pharmacy industry in China is undergoing significant challenges, with a trend of store closures and a shift from aggressive expansion to a focus on quality and efficiency [3][4][10]. Group 1: Store Closures and Industry Trends - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, have reported a continued strategy of closing underperforming stores while slowing down expansion efforts [3][4]. - In Q1 2025, Lao Bai Xing and Shu Yu Ping Min closed 161 and 86 stores respectively, while Yi Feng Pharmacy opened 94 stores but closed 84 [3][7]. - The overall closure rate in the retail pharmacy sector reached 5.7% in 2024, with over 39,000 stores shutting down [4][11]. Group 2: Financial Performance - Yi Feng Pharmacy reported Q1 2025 revenue of 600.9 million yuan, a year-on-year increase of 0.64%, while its net profit grew by 10.51% [7]. - In contrast, Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experienced revenue declines of 1.88%, 6.53%, and 0.85% respectively in Q1 2025 [7][8]. - The financial performance of many listed pharmacy chains has shown a decline in both revenue and profit, indicating a challenging market environment [6][8]. Group 3: Market Dynamics and Future Outlook - The retail pharmacy industry is experiencing a consolidation phase, driven by increased market concentration and regulatory pressures [10][14]. - The shift from rapid expansion to a focus on closing unprofitable stores and improving operational efficiency is becoming a new trend in the industry [10][12]. - Companies are exploring new retail models and diversifying their offerings to adapt to changing market conditions, with some focusing on integrating online and offline sales [14][15].

Core Viewpoint - The retail pharmacy industry in China is facing significant challenges, leading to a wave of store closures and a shift in focus from rapid expansion to improving operational efficiency and quality [1][6][8]. Group 1: Store Closures and Expansion Strategies - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, are continuing to close underperforming stores while slowing down their expansion efforts [1][4]. - In Q1 2025, Lao Bai Xing closed 161 stores and opened 24, while Yi Feng Pharmacy opened 94 stores (26 self-built and 68 franchises) but closed 84 [1][4]. - The overall closure rate for retail pharmacies reached 5.7% in 2024, with over 39,000 stores shutting down [1][6]. Group 2: Financial Performance - Financial reports for Q1 2025 show a mixed performance among major chains, with Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experiencing revenue and profit declines [3][4]. - Yi Feng Pharmacy reported a revenue of 6.009 billion yuan, up 0.64% year-on-year, and a net profit of 449 million yuan, up 10.51% [3][4]. - Dazheng Lin achieved a revenue of 6.956 billion yuan, up 3.02%, and a net profit of 460 million yuan, up 15.45% [3][4]. Group 3: Industry Trends and Challenges - The retail pharmacy sector is undergoing a deep transformation, moving from aggressive expansion to a focus on quality and efficiency due to market saturation and increased regulatory scrutiny [6][8]. - The number of pharmacies in China increased from 524,000 in 2019 to 667,000 in 2023, leading to structural oversupply [8][9]. - Industry experts predict that around 20% of small pharmacies may be eliminated, further increasing market concentration [8]. Group 4: New Retail Strategies - Leading chains are integrating online and offline operations to adapt to changing market dynamics, with Yi Feng Pharmacy reporting significant online sales growth [9][10]. - Dazheng Lin is focusing on building a prescription transfer system and enhancing professional service capabilities to differentiate itself in a competitive landscape [9][10]. - Yi Xin Tang is exploring diversification into non-pharmaceutical products and new business models, such as combining pharmacies with convenience stores [10].

| | | 漱玉平民大药房连锁股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会不存在变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）会议召开时间、地点及召开方式 漱玉平民大药房连锁股份有限公司（以下简称"公司"）2024 年年度股东大会于 2025 年 5 月 20 日下午 2:30 在山东省济南市历城区山大北路 56 号公司会议室以现场表决和网络 投票相结合的方式召开。通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行投 票的具体时间为 2025 年 5 月 20 日 9:15-15:00 的任意时间。 （2）会议召集人：公司董事会 （3）会议主持人：李文杰 （4）本次会议的召集、召开与表决程序符合《公司法》和《公司章程》的规定。 2、会议出席情况 （1）股东出席的总体情况： ...

北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的 法律意见 地址：山东省济南市高新区舜泰北路 567 号银丰科技公园 2 号楼 邮编：250102 网址：www.dehenglaw.com 电话：（86）531-8166 3606 北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的法律意见 北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2024 年年度股东大会的 法律意见 德恒 11G20230145-12 号 致：漱玉平民大药房连锁股份有限公司 北京德恒（济南）律师事务所（以下简称"本所"）作为漱玉平民大药房连 锁股份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派张璐 律师、赵程程律师（以下简称"本所律师"）出席公司 2024 年年度股东大会（以 下简称"本次股东大会"），依据《中华人民共和国公司法》（以下简称《公司 法》）、《上市公司股东大会规则》（以下简称《股东大会规则》）等现行有效 的法律、法规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》（以 下简称《公司章程》）、《漱玉平民大药 ...

Financial Performance - In 2024, the company achieved a total revenue of 9.57 billion CNY, representing a year-on-year growth of 4.13% [2] - The net profit attributable to shareholders was -189 million CNY, a significant decline of 241.90% compared to the previous year [2] - In Q1 2025, the company reported a revenue of 2.379 billion CNY, a decrease of 2.48% year-on-year, with a net profit of 25.6239 million CNY, marking a growth of 143.85% compared to the same period last year [3] Shareholder Information - As of April 30, 2025, the total number of shareholders is 13,133 [4] Growth Strategies - Future profit growth will focus on: - Expansion of store networks through self-built, mergers, franchises, and alliances [4] - Digital transformation and new retail strategies to enhance operational efficiency and online penetration [4] - Development of proprietary brands and diversification of product lines, including health products targeting younger demographics [4] - Optimization of logistics and supply chain systems to support franchise expansion and improve procurement cost structure [4] Industry Outlook - The pharmaceutical retail industry is expected to maintain steady growth due to structural adjustments and strategic opportunities driven by factors such as an aging population and increased health awareness [5] Acquisition Status - The company has terminated the acquisition of Tian Shili, as approved by the board on December 28, 2023 [6]

1. Report Industry Investment Rating - No relevant content provided 2. Core View of the Report - The report is about the research of Shuyu Pingmin, a company in the pharmaceutical commerce industry. It includes basic research information, details of research institutions, and responses to investors' questions [16][19][23] 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Shuyu Pingmin, belonging to the pharmaceutical commerce industry. The reception time was on May 15, 2025, and the company's reception staff included Director, Vice President, and Board Secretary Li Qiang, and Financial Controller Hu Qinhong [16] 3.2 Detailed Research Institutions - The reception object was the investors participating in the 2025 online collective reception day for listed company investors in Shandong Province, and the reception object type was Other [19] 3.3 Research Institution Proportion - No relevant content provided 3.4 Main Content Data - **Digital Innovation**: The company is accelerating the transformation to "smart pharmaceutical retail". It uses self - developed digital tools such as PDA, salary calculator, smart store inspection system, and "Yujian" cashier intelligent recommendation system to improve front - line service efficiency and customer medication service experience. In the intelligent supply chain field, it relies on algorithm models to optimize inventory management and uses digital tools to reduce manual operations and speed up inventory turnover. It also created the "Shuyu Zhiyuan" risk control platform to prevent business risks [23] - **Diversified Stores**: The company is about to open the "Dashu Shuyu" pharmacy in partnership with Dashu and Wangwang. This pharmacy features a diversified comprehensive pharmacy with a rich variety of products, including health and daily necessities, milk powder, baby products, nutritional supplements, medical devices, and cross - border products [23] - **Own Brand Development**: In 2024, the company's own - brand product business achieved a 9% year - on - year increase in full - channel sales, accounting for more than 13% of total retail sales [23] - **Asset - Liability Ratio**: The company's asset - liability ratio is slightly higher than the industry average due to its short listing time, small equity financing scale, and market expansion through mergers and acquisitions in recent years. The company will rely on the advantages of the listed platform for equity financing to keep the debt ratio at a reasonable level [25] - **Store Information**: As of the end of March 2025, the company had 8,916 stores in Shandong, Liaoning, Heilongjiang, Fujian, Henan, Gansu and other regions, including 4,353 direct - operated stores and 4,563 franchised stores [25]